Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 62

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 62
---
088 Denominator:Weighted average common shares outstanding used in Basic EPS716.3 740.6 Incremental common shares from:Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”)4.5 8.0 Weighted average common shares outstanding used in Diluted EPS720.8 748.6 Basic EPS $1.33 $1.47 Diluted EPS $1.32 $1.45 

NOTE 4.  REVENUE

The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 28, 2025 and March 29, 2024 ($ in millions).  Sales taxes and other usage-based taxes collected from customers are excluded from revenue.BiotechnologyLife SciencesDiagnosticsTotalFor the Three-Month Period Ended March 28, 2025:Geographical region:North America(a)$543 $721 $1,318 $2,582 Western Europe566 378 400 1,344 Other developed markets(b)64 123 91 278 High-growth markets(c)439 458 640 1,537 Total$1,612 $1,680 $2,449 $5,741 Revenue type:Recurring$1,457 $1,136 $2,223 $4,816 Nonrecurring155 544 226 925 Total$1,612 $1,680 $2,449 $5,741 For the Three-Month Period Ended March 29, 2024:Geographical region:North America(a)$514 $781 $1,337 $2,632 Western Europe546 372 406 1,324 Other developed markets(b)79 125 99 303 High-growth markets(c)385 467 685 1,537 Total$1,524 $1,745 $2,527 $5,796 Revenue type:Recurring$1,309 $1,192 $2,294 $4,795 Nonrecurring215 553 233 1,001 Total$1,524 $1,745 $2,527 $5,796 (a) The Company defines North America as the United States and